Tidal Investments LLC Buys 6,778 Shares of DaVita Inc. (NYSE:DVA)

Tidal Investments LLC grew its stake in shares of DaVita Inc. (NYSE:DVA - Free Report) by 119.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 12,466 shares of the company's stock after buying an additional 6,778 shares during the quarter. Tidal Investments LLC's holdings in DaVita were worth $1,864,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of DVA. State of Wyoming lifted its holdings in DaVita by 59.6% in the fourth quarter. State of Wyoming now owns 2,020 shares of the company's stock worth $302,000 after buying an additional 754 shares during the period. Siemens Fonds Invest GmbH bought a new stake in shares of DaVita in the 4th quarter worth about $603,000. Rafferty Asset Management LLC grew its holdings in DaVita by 9.4% during the 4th quarter. Rafferty Asset Management LLC now owns 5,118 shares of the company's stock valued at $765,000 after purchasing an additional 438 shares during the last quarter. Raiffeisen Bank International AG bought a new position in DaVita in the 4th quarter worth about $371,000. Finally, ProShare Advisors LLC lifted its position in shares of DaVita by 9.6% in the 4th quarter. ProShare Advisors LLC now owns 6,817 shares of the company's stock worth $1,019,000 after purchasing an additional 598 shares during the period. 90.12% of the stock is currently owned by hedge funds and other institutional investors.

DaVita Trading Down 0.7%

Shares of DaVita stock traded down $1.01 during trading on Thursday, hitting $135.66. 295,451 shares of the company were exchanged, compared to its average volume of 821,877. The firm has a market capitalization of $10.24 billion, a P/E ratio of 12.63, a price-to-earnings-growth ratio of 1.07 and a beta of 1.14. The firm's fifty day moving average price is $144.67 and its 200 day moving average price is $153.13. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.26 and a quick ratio of 1.21. DaVita Inc. has a 1-year low of $131.76 and a 1-year high of $179.60.

DaVita (NYSE:DVA - Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The company reported $2.00 earnings per share for the quarter, beating analysts' consensus estimates of $1.75 by $0.25. DaVita had a return on equity of 115.48% and a net margin of 7.31%. The business had revenue of $3.22 billion for the quarter, compared to analysts' expectations of $3.22 billion. During the same quarter in the prior year, the business earned $2.26 EPS. The firm's revenue for the quarter was up 5.0% on a year-over-year basis. As a group, sell-side analysts expect that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms recently commented on DVA. Wall Street Zen upgraded shares of DaVita from a "hold" rating to a "buy" rating in a research report on Friday, April 25th. Cowen restated a "hold" rating on shares of DaVita in a research report on Tuesday, February 18th. Sanford C. Bernstein set a $184.00 target price on shares of DaVita in a report on Friday, February 21st. Barclays lifted their price target on shares of DaVita from $164.00 to $169.00 and gave the company an "equal weight" rating in a research report on Tuesday, February 18th. Finally, Truist Financial lowered their target price on shares of DaVita from $170.00 to $164.00 and set a "hold" rating for the company in a research note on Monday, May 19th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $164.50.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.